Connexon and Advanced Cell & Gene Therapy Launch Directory for the Cell and Gene Therapy Community
News Jun 06, 2008
Connexon Creative Inc. (Connexon) and Advanced Cell & Gene Therapy have announced the launch of The Cell Therapy Pages, a comprehensive directory of the cell and gene therapy community.
The Cell Therapy Pages is a searchable online database of over 1,800 organizations involved in cell therapy, gene therapy, cell-based immunotherapy, tissue engineering and regenerative medicine worldwide.
"The Cell Therapy Pages includes a unique classification scheme for industry and academic organizations, based on the type of products or services they provide or therapeutics they develop," said Tiffany Chiu, Connexon's Director Operations & Business Development.
"This classification system allows users to quickly find the information they need and connect with potential customers and suppliers."
Members of the cell and gene therapy community can also submit and update their organizations' listings and purchase subscriptions through the interactive website at http://www.celltherapypages.com/.
"The Cell Therapy Pages has been designed for the cell and gene therapy community, by people working in cell and gene therapy," commented Dr. Scott Burger, Principal of Advanced Cell & Gene Therapy.
"This resource will enable more effective development of these novel products by providing readily accessible information about companies developing cell- and gene-based therapeutics, sources of key products and services and academic investigators," Burger added.
The Cell Therapy Pages has been endorsed by the International Society for Cellular Therapy, as a publication that "is consistent with the standards of the International Society for Cellular Therapy (ISCT) and will support the development of the fields of cellular therapy, gene therapy, immunotherapy, tissue engineering and RNA interference."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.